Once a high-flying pioneer in China's heart valve market, VENUS MEDTECH-B (02500.HK) is now struggling with severe liquidity pressures. The company recently announced the discounted sale of its Hangzhou health industrial park for 375 million yuan, 12% below valuation, with most proceeds earmarked for debt repayment. While this move temporarily alleviates financial strain, it reveals deeper operational challenges.

I. Aggressive Expansion Backfires as Cash Reserves Dwindle VENUS MEDTECH-B's troubles have been brewing for years. At its 2021 peak with a 42.7 billion HKD market cap and nearly 3 billion yuan cash reserves, the company launched an ambitious 1.6 billion yuan industrial park project. This expansion proved disproportionate to actual revenue, which stagnated between 400-500 million yuan annually from 2021-2024.

The industrial park became a financial drain, absorbing 310 million yuan by end-2024 with another 700 million yuan required. Current cash reserves stand at just 279 million yuan as of June 2025, against 419 million yuan in borrowings. The company even diverted 73 million yuan from R&D funds to cover costs, signaling critical liquidity issues.

II. Stagnant Core Business Meets Procurement Policy Headwinds More concerning is the slowdown in core operations. With 11 competing heart valve products now approved in China, VENUS MEDTECH-B's H1 2025 revenue dropped 18.9% YoY. While its VenusA series contributes 83% of revenue, growth prospects appear dim.

Compounding the problem, heart valves were recently included in provincial group purchasing programs that directly overlap with VENUS MEDTECH-B's product line. Though regional pilot programs saw modest 11.49% average price cuts, nationwide procurement could further erode margins. The company's ability to offset price reductions through volume growth remains uncertain.

III. Governance Scandals Compound Market Distrust Beyond operational pressures, governance issues have damaged investor confidence. A 475-day trading suspension in November 2023 following executive embezzlement allegations preceded significant market cap erosion. The discounted asset sale to Hangzhou state investors, while addressing immediate needs, highlights the company's weak financing capabilities and strategic instability.

Conclusion The property sale provides only temporary relief. Facing the triple threat of procurement reforms, intense competition and cash constraints, VENUS MEDTECH-B must urgently refocus operations, control costs and develop new growth drivers. Without swift turnaround measures, even its former industry leadership position may not prevent market obsolescence.